Compare Gilead Sciences, Inc. (GILD) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Noble Corporation plc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Noble Corporation plc trades at $40.19 (market cap $6.54B). The key difference: Gilead Sciences, Inc. is far larger — about 27.8× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.88%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Noble Corporation plc for 26 Days on average.
| GILD | NE | |
|---|---|---|
Market Cap | $182.09B | $6.54B |
Volume | 4,960,247 | 1,192,391 |
Sector | Health | Energy |
52-Week High | $155.80 | $54.37 |
52-Week Low | $116.74 | $26.70 |
Typical Hold Time | 111 Days | 26 Days |
Enterprise Value | $205.15B | $7.97B |
Dividend Yield | 2.23% | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Noble Corporation (NE) trades at $40.97, down 1.16% on the day, with a bearish technical signal driven by moving averages and ADX indicators. The stock's valuation shows a P/E of 43.59 and P/S of 2.14, while recent earnings have been mixed with two misses and one beat in the last three quarters. A long-term drilling contract in Ghana provides operational stability, but investor sentiment is tempered by an ongoing legal investigation noted in recent news.
The outlook for NE is cautious; analyst consensus is a Buy with a $52 price target, implying potential upside, but risks include earnings volatility and legal scrutiny. Positive cash flow and a dividend payment support income investors, yet the bearish technical trend and declining revenue in 2026 warrant close monitoring for any fundamental deterioration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
